Publication:
The evaluation of magee equation 2 in predicting response and outcome in hormone receptor-positive and HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

Simple item page
dc.contributor.authorNapat Saigosoomen_US
dc.contributor.authorDoonyapat Sa-Nguanraksaen_US
dc.contributor.authorEng O-Charoenraten_US
dc.contributor.authorThanawat Thumrongtaradolen_US
dc.contributor.authorPornchai O-Charoenraten_US
dc.contributor.otherUCLen_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.date.accessioned2020-06-02T05:20:58Z
dc.date.available2020-06-02T05:20:58Z
dc.date.issued2020-01-01en_US
dc.description.abstract© 2020 Saigosoom et al. Background and Purpose: Magee Equations have been developed as accurate tools for predicting response and clinical outcomes in breast cancer patients treated with adjuvant systemic therapy using basic clinicopathological parameters. This study aims to evaluate the alternative application of Magee Equation 2 score in predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in hormone receptor (HR)-positive, HER2- negative breast cancer. Patients and Methods: Patients with HR-positive, HER2-negative breast cancer who received NAC from January 2010 to May 2018 at Siriraj Hospital, Mahidol University, Thailand, were recruited. Pre-treatment status of HR andHER2was used to calculate the Magee Equation 2 scores. The pCR rates among different clinicopathological parameters were analyzed. Survival analysis was performed by Log-rank test. Kaplan-Meier survival curves were analyzed. Results: A total of 215 patients were eligible. The pCR rates for low, intermediate, and high scores were 4.8%, 3.6%, and 23.8%, respectively. Patients with high scores had significantly higher size reduction and pCR rates compared to those with intermediate or low scores (p<0.001). Those with high scores had higher rates of locoregional recurrence and death. The patients with high score had significantly lower overall survival (p=0.034). Conclusion: Among patients with HR-positive and HER2-negative breast cancer treated with NAC, Magee Equation 2 might be used as a tool for predicting the pCR and clinical outcome.en_US
dc.identifier.citationCancer Management and Research. Vol.12, (2020), 2491-2499en_US
dc.identifier.doi10.2147/CMAR.S237423en_US
dc.identifier.issn11791322en_US
dc.identifier.other2-s2.0-85084211127en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14594/56307
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85084211127&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleThe evaluation of magee equation 2 in predicting response and outcome in hormone receptor-positive and HER2-negative breast cancer patients receiving neoadjuvant chemotherapyen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85084211127&origin=inwarden_US
Files
Collections
Scopus 2020